Skip to main content


Figure 1 | Breast Cancer Research

Figure 1

From: Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF

Figure 1

Tissue factor pathway inhibitor (TFPI) and tissue factor (TF) mRNA expression across molecular breast cancer subtypes. Box and whisker plot showing the distribution of log2-transformed total TFPI (α + β), TFPIα, and TFPIβ (A), and TF tumor mRNA expression (B) across the following intrinsic molecular subtypes of 150 of the 152 breast cancer patients; basal (n = 25), human epidermal growth factor 2 (HER2)-enriched (n = 15), luminal A (n = 63), luminal B (n = 39) and normal-like (n = 8). P-values for multi-group comparison are indicated.

Back to article page